Moximed, a medical device company, received marketing authorization from the FDA for its MISHA Knee System on April 10th, 2023. The Atlas unicompartmental knee system (Moximed Inc., Hayward, CA) is a novel alternative for patients with mild to moderate medial knee OA (Osteoarthritis).
The implantable shock absorber (ISA) is designed for individuals with medial knee OA who have not found relief from non-surgical or surgical interventions and are either ineligible or unwilling to undergo joint replacement.
Knee osteoarthritis affects millions of adults in the United States, and the MISHA Knee System is the first implantable shock absorber developed for treating medial compartment knee osteoarthritis. The device has demonstrated superiority over high tibial osteotomy in a clinical study and can significantly improve patient’s quality of life. The approval of the MISHA Knee System by the FDA validates Moximed’s commitment to improving patient outcomes and could potentially change the lives of millions of people.
Knee osteoarthritis is a prevalent condition that affects millions of adults in the United States. The MISHA Knee System is a groundbreaking solution as it is the first implantable shock absorber developed explicitly for treating medial compartment knee osteoarthritis. In a recent clinical study, this knee system has demonstrated superiority over high tibial osteotomy.
By decreasing weight on the knee joint with every walking step, the MISHA Knee System may significantly improve the patient’s overall quality of life by reducing pain and increasing mobility. Knee osteoarthritis is a prevalent degenerative joint disease affecting millions of individuals globally.
This condition can cause inflammation, pain, and stiffness in the joints, making it challenging to perform daily activities. While several treatment options are available, some patients may not find relief from these options or may not be suitable candidates for surgery. This is where the MISHA Knee System comes into play, offering a new, innovative solution for those who have exhausted other treatment options.
The MISHA Knee System is a remarkable medical innovation that addresses the unmet needs of individuals with knee osteoarthritis. The purpose of this implantable shock absorber is to alleviate the load on the medial compartment of the knee joint, resulting in pain relief and increased mobility. As patients take every step, the device absorbs and redistributes the weight, protecting the joint from further damage. This unique mechanism of action distinguishes the MISHA Knee System from other treatment options for knee osteoarthritis.
The FDA’s approval of the MISHA Knee System is a significant milestone for Moximed and the medical community. This innovative medical device offers a new option for people with knee osteoarthritis, potentially changing the lives of millions. Clinical studies have demonstrated the MISHA Knee System’s safety and effectiveness, showing it to be superior to the usual surgical treatment.
The MISHA Knee System is also an excellent choice for people who want to skip surgery’s potential dangers and downtime. Its unique mechanism of action reduces pain and improves mobility, allowing patients to regain their quality of life. This approval validates Moximed’s commitment to improving patient outcomes, offering a game-changing solution for knee osteoarthritis treatment.
